Lymphoma Coalition publishes research on the experiences of patients and care partners based on learnings from the Global Patient Survey on Lymphomas and CLL (GPS) and other projects.
It is imperative the issues raised by patients and their care partners through the biennial survey, interviews, focus groups and other initiatives are conveyed to the medical and research communities to improve care moving forward.
[{"id":40010,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/barriers-to-clinical-trial-information-in-relapsed-refractory-lymphoma-patients-post-sct\/","name":"barriers-to-clinical-trial-information-in-relapsed-refractory-lymphoma-patients-post-sct","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Demographic-Barriers-to-Clinical-Trial-Information-in-RR-Lymphoma-Patients-PostSCT.png","alt":""},"title":"Demographic Barriers to Clinical Trial Information in R\/R Lymphoma Patients Post-SCT","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Apr 26, 2023","dateGMT":"2023-04-26 17:38:00","modifiedDate":"2025-10-14 14:54:06","modifiedDateGMT":"2025-10-14 14:54:06","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":46},"status":"publish","excerpt":"Presented at the 49th Annual European Society for Blood and Marrow Transplantation (EBMT) meeting, in Paris France, 22-26 April 2023. Lymphoma Coalition (LC) supports almost 90 patient organizations across more than 50 countries. LC\u2019s overarching goal is to facilitate a community of patient organizations supporting efforts to help patients with lymphoma receive optimal care and support.\n\nStem Cell Transplant (SCT) and clinical trials involving new treatments provide increased opportunities for longer-lasting remission in patients with lymphoma with relapsed or refractory disease. However, not all patients are given information or the opportunity to access clinical trials.\n\nThis study investigates the potential socioeconomic barriers to receiving information on clinical trials or the opportunity to participate in them for patients with lymphoma who have previously received SCT."},{"id":40034,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/psychosocial-experiences-in-relapsed-refractory-dlbcl-car-t-vs-other-therapies\/","name":"psychosocial-experiences-in-relapsed-refractory-dlbcl-car-t-vs-other-therapies","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Abstract_96-Psychosocial-CART-vs-non-CART-1-1.png","alt":""},"title":"Psychosocial Experiences in Relapsed\/Refractory DLBCL: CAR-T vs. Other Therapies","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Feb 11, 2022","dateGMT":"2022-02-11 18:02:00","modifiedDate":"2025-10-14 15:07:41","modifiedDateGMT":"2025-10-14 15:07:41","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":41},"status":"publish","excerpt":"Presented during the \u201cBest Abstract Session\u201d at the 5th European CAR-T Cell Meeting in Rotterdam, The Netherlands, February 9-11. Chimeric antigen receptor T-cell (CAR-T) therapy continues to expand as a treatment option for patients with relapsed\/refractory diffuse large B cell lymphoma (DLBCL). This study provides insight into the psychosocial experiences of patients with relapsed and refractory DLBCL treated with CAR-T compared to other therapies."}]